Evelo Biosciences, Inc. (EVLO): Price and Financial Metrics


Evelo Biosciences, Inc. (EVLO): $2.22

0.15 (+7.25%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add EVLO to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

EVLO Stock Price Chart Interactive Chart >

Price chart for EVLO

EVLO Price/Volume Stats

Current price $2.22 52-week high $14.77
Prev. close $2.07 52-week low $1.42
Day low $2.02 Volume 576,600
Day high $2.32 Avg. volume 354,985
50-day MA $2.17 Dividend yield N/A
200-day MA $5.23 Market Cap 119.13M

Evelo Biosciences, Inc. (EVLO) Company Bio


Evelo Biosciences, Inc. focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815 for patients with psoriasis and atopic dermatitis, rheumatoid arthritis, and ulcerative colitis/crohn’s colitis; and EDP1503 for the treatment of colorectal cancer, renal cell carcinoma, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment across multiple tumor types. The company was founded in 2014 and is based in Cambridge, Massachusetts.


EVLO Latest News Stream


Event/Time News Detail
Loading, please wait...

EVLO Latest Social Stream


Loading social stream, please wait...

View Full EVLO Social Stream

Latest EVLO News From Around the Web

Below are the latest news stories about Evelo Biosciences Inc that investors may wish to consider to help them evaluate EVLO as an investment opportunity.

5 Drug/Biotech Stocks Set to Outpace Q4 Earnings Estimates

Let us take a look at some drug/biotech stocks, EVLO, GMDA, APLS, MRTX and ITOS, which are poised to beat on fourth-quarter earnings.

Yahoo | February 24, 2022

Evelo Biosciences begins dosing in phase 2 trial of EDP1815 for eczema

Evelo Biosciences (EVLO) said the first patient was dosed in a phase 2 trial of EDP1815 to treat patients with mild, moderate, and severe atopic dermatitis, also known…

Seeking Alpha | February 17, 2022

Evelo Biosciences Announces Dosing of First Patient in Phase 2 Trial of EDP1815 in Atopic Dermatitis

CAMBRIDGE, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that the first patient has been dosed in EDP1815-207, its Phase 2 randomized clinical trial of EDP1815 for the treatment of patients with mild, moderate, and severe atopic dermatitis. “We are pleased that dosing has begun in the Phase 2 trial to eval

Yahoo | February 17, 2022

INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANT

Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agricultural, sustainability, and environmental challenges, today announced the appointment of Hugh Grant to its Board of Directors.

Yahoo | February 15, 2022

Evelo Biosciences, Inc. (EVLO) Upgraded to Buy: Here's What You Should Know

Evelo Biosciences, Inc. (EVLO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Yahoo | February 11, 2022

Read More 'EVLO' Stories Here

EVLO Price Returns

1-mo 4.72%
3-mo -33.73%
6-mo -64.59%
1-year -84.24%
3-year -75.28%
5-year N/A
YTD -63.43%
2021 -49.79%
2020 197.78%
2019 -68.79%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7134 seconds.